Preparing for China · patient guide

Familial Mediterranean fever in China at a glance

Familial Mediterranean fever is a lifelong inherited inflammatory condition, and care in China begins with a records-based specialist review rather than a procedure. There is no single China-wide pathway, so the practical question is whether a rheumatology or immunology team can confirm your diagnosis, review your current treatment and advise on monitoring. Hospital acceptance and any treatment decision remain with the treating clinicians.

Go to the practical guidance ↓
AI illustration: A couple attentively listens to a woman in a professional setting, seated around a wooden table with folders and a potted plant.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What familial Mediterranean fever is and why the diagnosis matters

Familial Mediterranean fever (FMF) is an autoinflammatory condition caused by inherited changes in the MEFV gene. It produces recurrent episodes of fever and serosal inflammation, typically abdominal, chest or joint pain, and it can lead to a serious complication called amyloidosis if inflammation is poorly controlled over time. Because the condition is genetic and lifelong, the central clinical tasks are confirming the diagnosis, controlling inflammation and monitoring for complications, not performing a one-off procedure.

This matters for planning care in China because the value of a specialist visit depends heavily on what has already been established. If your diagnosis is genetically and clinically confirmed, a Chinese rheumatology or immunology team can review your history and current management. If the diagnosis is still uncertain, the appointment becomes a diagnostic assessment, and the questions you bring are different. Either way, the treating clinicians decide what tests or treatment changes are appropriate; an enquiry or coordination service does not.

FMF is uncommon outside Mediterranean populations, and awareness varies between clinicians and hospitals. That is a practical reason to ask, before travelling, whether the specific department has experience with autoinflammatory disease and how it would approach an established FMF diagnosis. Do not assume that a large hospital automatically has a dedicated FMF service.

Rare disease assessment and care planning

The decision to clarify before booking: review or first diagnosis

Overseas patients usually arrive with one of two situations. The first is a confirmed FMF diagnosis, often with genetic testing and a treatment history, where the goal is a second opinion on control of inflammation, monitoring or treatment options. The second is a suspected but unconfirmed diagnosis, where recurrent fevers have not been fully explained. These are genuinely different requests, and mixing them up leads to wasted appointments.

For a confirmed diagnosis, the useful question is whether your current regimen is controlling inflammation adequately and whether monitoring for amyloidosis and other complications is in place. For an unconfirmed diagnosis, the useful question is what the team would need to reach or exclude FMF, including which genetic and inflammatory tests it considers relevant. In both cases, the clinician decides, and the answer may be that further local assessment is needed first.

It also helps to be clear about what you are not asking for. A records-based opinion is not a guarantee of hospital acceptance, and it does not replace an in-person examination. If your symptoms are severe or worsening, local urgent assessment takes priority over planning travel. The purpose of an overseas review is to add specialist perspective, not to delay necessary care at home.

Records that make a specialist review useful

FMF assessment relies on a clear narrative of attacks and on laboratory and genetic evidence. A specialist reading your file remotely or in person benefits from organised records rather than a large unlabelled archive. Ask your current clinicians which documents best summarise your case, and send a short summary first rather than a complete medical history at the initial contact.

Useful items typically include a chronological summary of fever and pain episodes with dates and what was found during them, results of any genetic testing for MEFV variants, inflammatory markers measured between and during attacks, kidney function and urine protein results relevant to amyloidosis monitoring, and a list of current and previous medicines with doses and responses. If you have had imaging or procedures during attacks, a brief note of findings helps.

You do not need every document before making an enquiry. A short summary lets the team identify what is missing and what the next step should be. Ask the receiving clinician which records they consider essential for your situation rather than assuming a universal checklist applies.

  • A dated summary of attacks and what happened during them
  • Genetic test reports, including which gene panel was used
  • Inflammatory marker results over time, not a single value
  • Kidney and urine protein monitoring results
  • Current and past medicines with doses and response
  • A short list of your main questions for the specialist

Treatment questions to put to the treating team

FMF management is a specialist clinical matter, and this article does not recommend medicines or doses. What you can do is prepare precise questions so the appointment is productive. Established care generally centres on controlling inflammation continuously and monitoring for complications, but the specific approach depends on your history, kidney function, pregnancy plans and other conditions.

Ask whether your current treatment is achieving adequate control, what monitoring the team would recommend and how often, and what would prompt a change in plan. If you are considering pregnancy or have kidney concerns, raise these explicitly, because they can affect which options are suitable. Ask what the team would do if attacks continue despite treatment, and what alternatives it considers appropriate for your case.

It is also reasonable to ask how the team handles long-term follow-up for an international patient. FMF is managed over years, so a single visit is rarely the whole answer. Clarify whether follow-up can be done with your local clinicians, what information the China team would need to support that, and how communication would work between visits. These are practical questions the hospital can answer; do not assume a particular arrangement.

What a China specialist route can and cannot settle

China has large tertiary hospitals with rheumatology, immunology, nephrology and genetics departments, and an autoinflammatory diagnosis may sit across more than one of these. For a complex case, a review involving several specialties can be discussed, with the scope agreed in advance. The hospital, not a coordination service, decides whether it will accept the case and what assessment is appropriate.

A records-based specialist opinion can help you understand your options and prepare questions, but it does not establish final eligibility for any treatment, access to a particular medicine, or a clinical outcome. Availability of specific medicines in China is a separate question that the treating hospital and pharmacy must confirm for your situation. Do not treat a positive preliminary reply as confirmation that a treatment plan is available.

If your case is complex or crosses specialties, a multidisciplinary review may be a sensible route to discuss. The scope and any coordination fee are agreed first, and hospital charges are separate. An initial enquiry is free and does not require buying a proxy consultation; a proxy consultation is optional and is not a prerequisite for every appointment.

Practical planning and a clear next step

Once a specialist route is identified, plan around the clinical questions rather than a fixed itinerary. Confirm with the hospital what the appointment will cover, which records it wants in advance, whether interpretation is needed and how results will be shared with you afterwards. Ask what would make the visit worthwhile and what could be handled remotely instead.

Travel and language arrangements are practical matters that can be discussed separately from clinical decisions. Keep your local clinicians informed of any plan, and do not stop or change treatment on your own while arranging a review. If your condition worsens, seek local care rather than waiting for an overseas appointment.

A sensible next step is to send a brief summary of your diagnosis status, current treatment and main question through the enquiry form, email or WhatsApp. The team can then indicate what information is missing and which specialist route may fit. This initial review is not a diagnosis and does not promise hospital acceptance; the treating clinicians make the clinical decisions.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Rare disease assessment and care planning
  2. procedures

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.